Biochemical markers of bone turnover in tibia fracture patients randomly assigned to growth hormone (GH) or placebo injections. Implications for detection of GH abuse

Growth Hormone and IGF Research

Volumn 21, Issue 6, 2011, Pages 331-335

  Krusenstjerna Hafstrøm, Thomas ^a   Rasmussen, Michael Højby ^b   Raschke, Michael ^d   Govender, Shunmugam ^c   Madsen, Jesper ^b   Christiansen, Jens Sandahl ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b NOVO NORDISK A S   (Denmark)

^c Departments of Orthopaedic Surgery   (South Africa)

^d UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Biological markers; Doping in sports; Fractures; Human growth hormone; Osteocalcin

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; BIOCHEMICAL MARKER; CARBOXY TERMINAL TELOPEPTIDE; HUMAN GROWTH HORMONE; OSTEOCALCIN; PLACEBO; SOMATOMEDIN C;

ADULT; AGED; ARTICLE; BONE TURNOVER; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CONVALESCENCE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; FEMALE; FRACTURE HEALING; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TIBIA FRACTURE; TREATMENT DURATION;

ADOLESCENT; ADULT; AGED; ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; BONE REMODELING; COLLAGEN TYPE I; DOPING IN SPORTS; DOUBLE-BLIND METHOD; FEMALE; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; OSTEOCALCIN; PEPTIDES; TIBIAL FRACTURES; YOUNG ADULT;

EID: 80055071441     PISSN: 10966374     EISSN: 15322238     Source Type: Journal    
DOI: 10.1016/j.ghir.2011.08.003     Document Type: Article

References (38)

1. Birchard K. Why doctors should worry about doping in sport. Lancet 1998, 352(9121):42.
2. Holt R.I., Sonksen P.H. Growth hormone, IGF-I and insulin and their abuse in sport. Br. J. Pharmacol. 2008, 154(3):542-556.
3. Liu H., Bravata D.M., Olkin I., et al. Systematic review: the effects of growth hormone on athletic performance. Ann. Intern. Med. 2008, 148(10):747-758.
4. Meinhardt U., Nelson A.E., Hansen J.L., et al. The effects of growth hormone on body composition and physical performance in recreational athletes: a randomized trial. Ann. Intern. Med. 2010, 152(9):568-577.
5. Evans W.S., Faria A.C., Christiansen E., et al. Impact of intensive venous sampling on characterization of pulsatile GH release. Am. J. Physiol. 1987, 252(4 Pt 1):E549-E556.
6. Le R.D. Seminars in medicine of the Beth Israel Deaconess Medical Center. Insulin-like growth factors. N. Engl. J. Med. 1997, 336(9):633-640.
7. Hakkinen K., Pakarinen A. Acute hormonal responses to two different fatiguing heavy-resistance protocols in male athletes. J. Appl. Physiol. 1993, 74(2):882-887.
8. Koistinen H., Koistinen R., Selenius L., Ylikorkala Q., Seppala M. Effect of marathon run on serum IGF-I and IGF-binding protein 1 and 3 levels. J. Appl. Physiol. 1996, 80(3):760-764.
9. Hakkinen K., Pakarinen A. Acute hormonal responses to heavy resistance exercise in men and women at different ages. Int. J. Sports Med. 1995, 16(8):507-513.
10. Sutton J., Lazarus L. Growth hormone in exercise: comparison of physiological and pharmacological stimuli. J. Appl. Physiol. 1976, 41(4):523-527.
11. Bunt J.C., Boileau R.A., Bahr J.M., Nelson R.A. Sex and training differences in human growth hormone levels during prolonged exercise. J. Appl. Physiol. 1986, 61(5):1796-1801.
12. Gibney J., Healy M.L., Sonksen P.H. The growth hormone/insulin-like growth factor-I axis in exercise and sport. Endocr. Rev. 2007, 28(6):603-624.
13. Dall R., Lange K.H., Kjaer M., et al. No evidence of insulin-like growth factor-binding protein 3 proteolysis during a maximal exercise test in elite athletes. J. Clin. Endocrinol. Metab. 2001, 86(2):669-674.
14. Longobardi S., Keay N., Ehrnborg C., et al. Growth hormone (GH) effects on bone and collagen turnover in healthy adults and its potential as a marker of GH abuse in sports: a double blind, placebo-controlled study. The GH-2000 Study Group. J. Clin. Endocrinol. Metab. 2000, 85(4):1505-1512.
15. Powrie J.K., Bassett E.E., Rosen T., et al. Detection of growth hormone abuse in sport. Growth Horm. IGF Res. 2007, 17(3):220-226.
16. Holt R.I., Bassett E.E., Erotokritou-Mulligan I., et al. Moving one step closer to catching the GH cheats: the GH-2004 experience. Growth Horm. IGF Res. 2009, 19(4):346-351.
17. Wallace J.D., Cuneo R.C., Lundberg P.A., et al. Responses of markers of bone and collagen turnover to exercise, growth hormone (GH) administration, and GH withdrawal in trained adult males. J. Clin. Endocrinol. Metab. 2000, 85(1):124-133.
18. Erotokritou-Mulligan I., Bassett E.E., Bartlett C., et al. The effect of sports injury on insulin-like growth factor-I and type 3 procollagen: implications for detection of growth hormone abuse in athletes. J. Clin. Endocrinol. Metab. 2008, 93(7):2760-2763.
19. Raschke M., Rasmussen M.H., Govender S., Segal D., Suntum M., Christiansen J.S. Effects of growth hormone in patients with tibial fracture: a randomised, double-blind, placebo-controlled clinical trial. Eur. J. Endocrinol. 2007, 156(3):341-351.
20. Moller N., Jorgensen J.O. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr. Rev. 2009, 30(2):152-177.
21. Ohlsson C., Bengtsson B.A., Isaksson O.G., Andreassen T.T., Slootweg M.C. Growth hormone and bone. Endocr. Rev. 1998, 19(1):55-79.
22. Brixen K., Nielsen H.K., Eriksen E.F., Charles P., Mosekilde L. Efficacy of wheat germ lectin-precipitated alkaline phosphatase in serum as an estimator of bone mineralization rate: comparison to serum total alkaline phosphatase and serum bone Gla-protein. Calcif. Tissue Int. 1989, 44(2):93-98.
23. Bradbeer J.N., Lindsay P.C., Reeve J. Fluctuation of mineral apposition rate at individual bone-remodeling sites in human iliac cancellous bone: independent correlations with osteoid width and osteoblastic alkaline phosphatase activity. J. Bone Miner. Res. 1994, 9(11):1679-1686.
24. Rosenquist C., Fledelius C., Christgau S., et al. Serum CrossLaps One Step ELISA. First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen. Clin. Chem. 1998, 44(11):2281-2289.
25. Bonde M., Qvist P., Fledelius C., Riis B.J., Christiansen C. Applications of an enzyme immunoassay for a new marker of bone resorption (CrossLaps): follow-up on hormone replacement therapy and osteoporosis risk assessment. J. Clin. Endocrinol. Metab. 1995, 80(3):864-868.
26. Prockop D.J., Kivirikko K.I. Collagens: molecular biology, diseases, and potentials for therapy. Annu. Rev. Biochem. 1995, 64:403-434.
27. Christgau S., Rosenquist C., Alexandersen P., et al. Clinical evaluation of the Serum CrossLaps One Step ELISA, a new assay measuring the serum concentration of bone-derived degradation products of type I collagen C-telopeptides. Clin. Chem. 1998, 44(11):2290-2300.
28. Healy M.L., Dall R., Gibney J., et al. Toward the development of a test for growth hormone (GH) abuse: a study of extreme physiological ranges of GH-dependent markers in 813 elite athletes in the postcompetition setting. J. Clin. Endocrinol. Metab. 2005, 90(2):641-649.
29. Thevis M., Bredehoft M., Kohler M., Schanzer W. Mass spectrometry-based analysis of IGF-1 and hGH. Handb. Exp. Pharmacol. 2010, 195:201-207.
30. Ding J., List E.O., Okada S., Kopchick J.J. Perspective: proteomic approach to detect biomarkers of human growth hormone. Growth Horm. IGF Res. 2009, 19(4):399-407.
31. Hoffman J.R., Kraemer W.J., Bhasin S., et al. Position stand on androgen and human growth hormone use. J. Strength Cond. Res. 2009, 23(5 Suppl.):S1-S59.
32. Wu Z., Bidlingmaier M., Dall R., Strasburger C.J. Detection of doping with human growth hormone. Lancet 1999, 353(9156):895.
33. Gutierrez-Gallego R., Bosch J., Such-Sanmartin G., Segura J. Surface plasmon resonance immuno assays - A perspective. Growth Horm. IGF Res. 2009, 19(4):388-398.
34. Pharmacology Travis J. Growth hormone test finally nabs first doper. Science 2010, 327(5970):1185.
35. Nelson A.E., Howe C.J., Nguyen T.V., et al. Influence of demographic factors and sport type on growth hormone-responsive markers in elite athletes. J. Clin. Endocrinol. Metab. 2006, 91(11):4424-4432.
36. Erotokritou-Mulligan I., Bassett E.E., Cowan D.A., et al. Influence of ethnicity on IGF-I and procollagen III peptide (P-III-P) in elite athletes and its effect on the ability to detect GH abuse. Clin. Endocrinol. (Oxf) 2009, 70(1):161-168.
37. Guha N., Erotokritou-Mulligan I., Burford C., et al. Serum insulin-like growth factor-I and pro-collagen type III N-terminal peptide in adolescent elite athletes: implications for the detection of growth hormone abuse in sport. J. Clin. Endocrinol. Metab. 2010, 95(6):2969-2976.
38. Bidlingmaier M., Strasburger C.J. Growth hormone. Handb. Exp. Pharmacol. 2010, 195:187-200.